Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Moderna Files BA.4/5-Tailored COVID-19 Vaccine in Japan
October 5, 2022
-
REGULATORY Japan Panel OKs Inclusion of Silgard 9 into National Immunization Program
October 5, 2022
-
BUSINESS Novartis Homes in on 5 Therapy Areas and 4 Markets, Eyes Top 3 Multinational Rank in Japan: CEO
October 4, 2022
-
BUSINESS Celltrion Aims to Market 11 Biosimilars in Japan, Infliximab “Biobetter” in the List
October 3, 2022
-
REGULATORY Japan Ends Supply of AstraZeneca’s COVID Jab, 13.5 Million Doses Discarded
October 3, 2022
-
REGULATORY Wholesalers Question Inflexibility in Official Pricing, Sees Limit to Addressing Rising Costs
September 30, 2022
-
BUSINESS Ferring Japan CEO Confident of Growth in Fertility Drugs Spurred by Rising Demand on Health Coverage
September 30, 2022
-
BUSINESS Lecanemab Hits PIII Mark with 27% Cut in Clinical Decline, Eisai Set for Submissions by March-End
September 29, 2022
-
ORGANIZATION Policy Veterans’ Group Proposes Simple Drug Price Maintenance Scheme for Patented Meds
September 28, 2022
-
REGULATORY Japan Approves Mounjaro, Tezspire, Fintepla, Label Expansions for Rinvoq/Skyrizi, Keytruda, and More
September 27, 2022
-
BUSINESS Ivermectin Misses Goal in PIII COVID-19 Trial: Kowa
September 27, 2022
-
REGULATORY Revamped Expert Panel Holds Industry Hearing, Discussions Center on Drug Price Gap
September 26, 2022
-
BUSINESS Janssen Aims to Rank Among Top 3 Drug Makers in Japan by 2024: Local Chief
September 22, 2022
-
REGULATORY 2 Years after Full Rollout, Sakigake System Shows Tepid Uptake as Industry Sees Poor Incentives
September 21, 2022
-
REGULATORY Japan Launches Omicron Booster Program for COVID-19
September 21, 2022
-
REGULATORY MHLW Retools New Expert Panel, Industry Hearing Set for Sept. 22
September 21, 2022
-
BUSINESS Boehringer Ingelheim Revamping Biz Sites in Japan to Spur Communications among Drug Reps
September 20, 2022
-
BUSINESS Insmed CEO Sees Japan as Cornerstone of APAC Strategy, Doubling of Staff in Next 2 Years
September 16, 2022
-
BUSINESS Moderna to Have One of Industry’s Biggest Pipelines in 5 Years, Oncology Might Make Up 30% of Sales: CEO
September 15, 2022
-
BUSINESS Alnylam Japan Paints Two-Digit Annual Growth Outlook on ATTR Meds and Pipeline Drugs
September 14, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…